ECSS
BMRN icon

Eurizon Capital SGR SpA’s BioMarin Pharmaceuticals BMRN Stock Holding History

Eurizon Capital SGR SpA’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$187K Sell
3,240
-7,912
-71% -$433K ﹤0.01% 761
2026
Q1 		$625K Sell
11,152
-1,152
-9% -$67.2K ﹤0.01% 647
2025
Q4 		$730K Buy
+12,304
New +$670K ﹤0.01% 553

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Eurizon Capital SGR SpA's BMRN Position: Q2 2026 in Review

Eurizon Capital SGR SpA reduced its BioMarin Pharmaceuticals (BMRN) stake by 71% in Q2 2026, selling an estimated $433K and leaving 3,240 shares worth $187K. The position accounts for ﹤0.01% of the portfolio, ranked #761.

Eurizon Capital SGR SpA first reported a position in BMRN in Q4 2025 and has held it in 3 quarters since. The position peaked at $730K in Q4 2025. 561 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Eurizon Capital SGR SpA held 3,240 shares of BioMarin Pharmaceuticals worth $187K as of Q2 2026.
  • Eurizon Capital SGR SpA sold 7,912 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $433K.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Eurizon Capital SGR SpA's portfolio in Q2 2026, its #761 holding.
  • Eurizon Capital SGR SpA first reported a position in BioMarin Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Eurizon Capital SGR SpA's BioMarin Pharmaceuticals position peaked at $730K in Q4 2025.
  • 561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Eurizon Capital SGR SpA's 13F filing for Q2 2026, filed 29 Jul 2026.